Diacylglycerol / ожиріння

Modulation of diacylglycerol acyltransferase 1 expression

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND OF THE INVENTION Triglycerides are one of the major energy storage molecules in eukaryotes. The absorption of triglycerides (also called triacylglycerols) from food is a very efficient process that occurs by a series of steps wherein the dietary triacylglycerols are hydrolyzed in the

Modulation of diacylglycerol acyltransferase 1 expression

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND OF THE INVENTION Triglycerides are one of the major energy storage molecules in eukaryotes. The absorption of triglycerides (also called triacylglycerols) from food is a very efficient process that occurs by a series of steps wherein the dietary triacylglycerols are hydrolyzed in the

Bicyclic compounds as inhibitors of diacylglycerol acyltransferase

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

FIELD OF THE INVENTION The present invention relates to certain heterocyclic compounds useful as diacylglycerol acyltransferase ("DGAT") inhibitors, especially diacylglycerol acyltransferase 1 ("DGAT1") inhibitors, pharmaceutical compositions containing the compounds, and methods of treatment using

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND OF THE INVENTION Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND OF THE INVENTION Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND OF THE INVENTION Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean

Inhibitors of diacylglycerol acyltransferase

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

FIELD OF THE INVENTION The invention involves inhibitors of diacylglycerol acyltransferase. The inhibitors are useful for the treatment of diseases such as obesity, type II diabetes mellitus, dyslipidemia and metabolic syndrome. All documents cited or relied upon below are expressly incorporated

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI >30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

BACKGROUND Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the

Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

INTRODUCTION 1. Field of the Invention The invention relates generally to methods of treating conditions associated with abnormal carbohydrate metabolism, such as obesity and diabetes. Specifically, the invention relates to methods of modulating insulin and/or leptin sensitivity in a host. 2.

Compounds as diacylglycerol acyltransferase inhibitors

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases

Compounds as diacylglycerol acyltransferase inhibitors

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases

Compounds as diacylglycerol acyltransferase inhibitors

Тільки зареєстровані користувачі можуть перекладати статті

Увійти Зареєструватися

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases

diacylglycerol/ожиріння

Modulation of diacylglycerol acyltransferase 1 expression

Modulation of diacylglycerol acyltransferase 1 expression

Bicyclic compounds as inhibitors of diacylglycerol acyltransferase

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

Inhibitors of diacylglycerol acyltransferase

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity

Compounds as diacylglycerol acyltransferase inhibitors

Compounds as diacylglycerol acyltransferase inhibitors

Compounds as diacylglycerol acyltransferase inhibitors

Найповніша база даних про лікарські трави, підкріплена наукою